What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives

about

What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives

Item

http://www.wikidata.org/entity/Q57159608

description

im September 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

What's New in Gastric Cancer: ...... ations and Future Perspectives

@en

What's New in Gastric Cancer: ...... ations and Future Perspectives

@nl

type

Item

label

What's New in Gastric Cancer: ...... ations and Future Perspectives

@en

What's New in Gastric Cancer: ...... ations and Future Perspectives

@nl

prefLabel

What's New in Gastric Cancer: ...... ations and Future Perspectives

@en

What's New in Gastric Cancer: ...... ations and Future Perspectives

@nl

P1476

What's New in Gastric Cancer: ...... ations and Future Perspectives

@en

P2093

Annalisa Pappalardo

http://www.w3.org/2001/XMLSchema#string

Ferdinando De Vita

http://www.w3.org/2001/XMLSchema#string

Gennaro Galizia

http://www.w3.org/2001/XMLSchema#string

Giuseppe Tirino

http://www.w3.org/2001/XMLSchema#string

Luca Pompella

http://www.w3.org/2001/XMLSchema#string

Maria Maddalena Laterza

http://www.w3.org/2001/XMLSchema#string

Marianna Caterino

http://www.w3.org/2001/XMLSchema#string

Michele Orditura

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin

Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer

Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

P304

2659

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.3390/IJMS19092659

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Fortunato Ciardiello

Angelica Petrillo

P5008

ScienceSource

P577

2018-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30205505

http://www.w3.org/2001/XMLSchema#string

P921

stomach cancer

molecular biology

catalysis

P932

6165492

http://www.w3.org/2001/XMLSchema#string